文献速递核素与放射性配体治疗肿瘤 PET/CT

放射性药物治疗中的辐射诱导衰老:机制与治疗意义

Radiation-Induced Senescence in Radiopharmaceutical Therapy: Mechanisms and Therapeutic Implications.
PubMed 文献 · J Nucl Med · 2026-10-01

本文综述放射性药物治疗(RPT)的放射生物学特征,指出RPT的低吸收剂量率易导致亚致死性辐射损伤并诱导细胞衰老。文章整合现有证据,提出RPT本质上是一种致衰老性放射治疗方式,并探讨将衰老靶向药物(senotherapeutics)与RPT联合以增强疗效、减少衰老相关不良效应的框架。

要点

  • RPT低吸收剂量率易致亚致死损伤,诱导肿瘤细胞衰老而非直接死亡。
  • 衰老在肿瘤中具双重作用,既促肿瘤又抑肿瘤,可成为治疗抵抗机制。
  • 本文首次将RPT放射生物学置于衰老分子机制框架下,提出RPT为内在致衰老性放射治疗。

核心结论

  • RPT是一种内在致衰老性放射治疗方式,衰老可能是其治疗抵抗机制及联合衰老靶向药物的靶点。

研究设计与样本

  • 本文为叙述性综述,整合现有关于RPT放射生物学与细胞衰老分子机制的文献证据。

主要发现

  • RPT的低吸收剂量率使治疗易产生亚致死性辐射损伤,导致衰老等替代性细胞命运。
  • 衰老是增殖性细胞停滞的稳定状态,在肿瘤中既具促肿瘤又具抗肿瘤的双重效应。
  • 现有文献多聚焦外照射诱导的衰老,少有报道探讨衰老在RPT情境中的作用。

临床怎么用

  • 可将衰老靶向药物(senotherapeutics)与RPT联合,通过处理辐射诱导的衰老负荷来增强疗效并减少衰老不良效应。

局限性

  • 现有文献多聚焦外照射诱导的衰老,RPT背景下衰老相关报道较少,证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiopharmaceutical therapy (RPT) has emerged as a radiation therapy modality with the distinctive ability to systemically treat metastatic disease by targeting specific biologic features expressed on cancer cells. Although the radiobiology of RPT remains incompletely understood, the low absorbed dose rates associated with RPT render these treatments prone to sublethal radiation damage, leading to alternative cell fates, such as senescence. In oncology, senescence-a stable state of proliferative cellular arrest-has been shown to act as a double-edged sword, providing both protumor and antitumor effects. The role of senescence in radiation therapy is of increasing interest as a mechanism of treatment resistance that, if targeted, may enhance tumor control and improve long-term treatment outcomes. Most current literature has focused on senescence induced by external beam radiation therapy, with few reports examining its role in the context of RPT. To our knowledge, this is the first review to contextualize RPT radiobiology within the molecular underpinnings of senescence, consolidate existing evidence, and propose a framework that recognizes RPT as an intrinsically senogenic radiation modality. Further, this review discusses opportunities for the combination of senescence-targeting drugs ("senotherapeutics") with RPT as a means of enhancing treatment efficacy by tackling the radiation-induced senescent burden and minimizing the deleterious effects of senescence.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lindsey MJ, Hernandez R. Radiation-Induced Senescence in Radiopharmaceutical Therapy: Mechanisms and Therapeutic Implications. J Nucl Med. 2026. PMID: 42350032. doi:10.2967/jnumed.126.272389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。